



## Living Cell Technologies Limited Company Announcement

### Results of the Annual General Meeting held on 28 November 2011

**28 November 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)**, the following voting results are in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today is provided in accordance with Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

#### Resolution 1: Adoption of Remuneration Report

"That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Directors' Report of the Company, for the year ended 30 June 2011 be adopted, details of which are set out in the explanatory notes to resolution 1 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
31,258,528	1,875,999	30,425,979

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
4,044,729	143,421	20,253,249	0

#### Resolution 2: Re-election of Mr Laurie Hunter as a Director

"That Mr Laurie Hunter, being a Director of the Company, retires by rotation in accordance with the Constitution and being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 2 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
56,936,996	1,822,149	10,230,340

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
26,577,310	89,571	0	0

### **Resolution 3: Election of Mr Roy Austin as a Director**

"That Mr Roy Austin, who was appointed a Director to fill a casual vacancy during the year, retires in accordance with the Constitution and being eligible, offers himself for election, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 3 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
67,115,413	1,813,578	60,494

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
26,585,881	81,000	0	0

### **Resolution 4: Election of Dr Bernard Tuch as a Director**

"That Dr Bernard Tuch, who was appointed a Director to fill a casual vacancy during the year, retires in accordance with the Constitution and being eligible, offers himself for election, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 4 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
31,815,496	1,812,578	35,361,411

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
26,586,881	80,000	0	0

### **Resolution 5: Election of Mr Robert Willcocks as a Director**

"That Mr Robert Willcocks, who was appointed a Director to fill a casual vacancy during the year, retires in accordance with the Constitution and being eligible, offers himself for election, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 5 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
56,930,567	1,828,578	10,230,340

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
26,570,881	96,000	0	0

## **Resolution 6 Ratification of Issue of Ordinary Shares Pursuant to ASX Listing Rule 7.4**

"That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 2,767,528 shares, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
36,694,747	1,812,578	30,482,160

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
6,373,632	20,293,249	0	0

## **Resolution 7: Approval of issue of options to Mr Roy Austin or his nominee in accordance with Listing Rule 10.11**

"That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.15 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.25 per share (Director options) and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.10 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.20 per share (Chairman options) to Roy Austin or his nominee, details of which are set out in the explanatory notes to resolution 7 in the notice of meeting".

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
36,463,364	22,260,424	10,265,697

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
6,157,606	20,489,275	20,000	0

## **Resolution 8 Approval of issue of options to Dr Bernard Tuch or his nominee in accordance with Listing Rule 10.11**

"That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.10 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.20 per share to Bernard Tuch or his nominee, details of which are set out in the explanatory notes to resolution 8 in the notice of meeting".

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
36,296,493	22,259,424	10,396,768

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
6,158,606	20,488,275	20,000	0

**Resolution 9 Approval of issue of options to Mr Robert Willcocks or his nominee in accordance with Listing Rule 10.11**

"That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.10 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.20 per share to Robert Willcocks or his nominee, details of which are set out in the explanatory notes to resolution 9 in the notice of meeting".

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
36,113,106	22,275,424	10,600,955

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
6,142,606	20,504,275	20,000	0

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the company:</b> Living Cell Technologies Limited Roy Austin, Chairman Tel: +64 9 9134605 Mobile: +64 21 656400 <a href="mailto:raustin@lctglobal.com">raustin@lctglobal.com</a></p> <p>Bob Elliott, Medical Director Tel: +64 9 2762690 Mobile: +64 272924177 <a href="mailto:belliott@lctglobal.com">belliott@lctglobal.com</a></p>	<p><b>Media and analyst enquiries:</b> Symbol Strategic Communications Patrick Sinclair/Robert Luttrell Tel: +61 2 8079 2969 Mobile: +61 403 708 431 <a href="mailto:psinclair@symbolstrategic.com.au">psinclair@symbolstrategic.com.au</a></p> <p>Robert Luttrell +61 419 185 652 <a href="mailto:rluttrell@symbolstrategic.com.au">rluttrell@symbolstrategic.com.au</a></p>
--	---

**About Living Cell Technologies** - [www.lctglobal.com](http://www.lctglobal.com)

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair

damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

***LCT Disclaimer***

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*